As of May, 18 AstraZeneca PLC (AZN) Analysts See $0.28 EPS

May 17, 2018 - By Antonio Nuckols

AstraZeneca PLC (NYSE:AZN) Corporate Logo

AstraZeneca PLC (NYSE:AZN)’s quarterly earnings will be published on May, 18 before the open., as reported by RTT. Analysts expect change of 71.72 % or $0.71 from previous year’s $0.99 earnings per share compared to current’s $0.28 earnings per share. If reported the P/E will be 32.59 with $697.23M profit. -78.46 % negative EPS growth is what analysts predict. $1.30 earnings per share was published for last quarter. The stock increased 0.72% or $0.26 during the last trading session, hitting $36.5.AstraZeneca PLC has volume of 3.44 million shares. Since May 17, 2017 AZN has risen 9.03% and is uptrending. AZN underperformed the S&P500 by 2.52%.

AstraZeneca PLC (NYSE:AZN) Ratings Coverage

In total 5 analysts cover AstraZeneca (NYSE:AZN). “Buy” rating has 4, “Sell” are 0, while 1 are “Hold”. (NYSE:AZN) has 80% bullish analysts. With $42.0 highest and $36.0 lowest target price, AstraZeneca has $40 average target price or 9.59% above the current ($36.5) price. 6 are the (NYSE:AZN)’s ratings reports on May 17, 2018 according to StockzIntelligence Inc. On Thursday, January 18 Leerink Swann maintained AstraZeneca PLC (NYSE:AZN) rating. Leerink Swann has “Hold” rating and $36.0 target. The stock rating was maintained by Bernstein with “Buy” on Monday, February 5. In Friday, December 29 report JP Morgan upgraded the stock to “Overweight” rating. In Tuesday, February 6 report Leerink Swann maintained the stock with “Market Perform” rating. On Friday, December 29 the firm has “Buy” rating given by J.P. Morgan. On Monday, March 19 the firm has “Buy” rating by Jefferies given.

AstraZeneca PLC discovers, develops, makes, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, infection, gastrointestinal, and neuroscience diseases worldwide.The firm is valued at $90.89 billion. The Company’s marketed products comprise Arimidex, Casodex/Cosudex, Faslodex, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Imdur, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Symlin, Xigduo, and Xigduo XR for metabolic diseases.The P/E ratio is 30.8. The companyÂ’s marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, and Symbicort Turbuhaler for respiratory diseases; Fluenz Tetra/FluMist Quadrivalent and Synagis for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, Vimovo1, and Zomig for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases.

A couple more AstraZeneca PLC (NYSE:AZN) news were posted by: Benzinga.com which released on April 20, 2018 “AstraZeneca Shares Are Looking Very Weak Right Now”, also Streetinsider.com on May 15, 2018 posted “AstraZeneca (AZN) PT Raised to $41 at BMO Capital”, the next Streetinsider.com is “AstraZeneca (AZN) Said to Weigh Sale of US Rights to Crestor, Could Fetch Over $1 Billion – Bloomberg” on May 16, 2018. Nasdaq.com has article titled “3 Dividend Stocks to Fund Your Nest Egg”.

AstraZeneca PLC (NYSE:AZN) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: